Protagonist Therapeutics Financials - Benzinga

Protagonist Therapeutics Inc

PTGXNASDAQ

Trade with Public

Trade with Public

$145.72

-3.08-2.07%

Last update: Sep 4, 5:30 PM

$145.00

-3.80-2.55%

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Protagonist Therapeutics Financials

Protagonist Therapeutics (PTGX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over losses of $(0.55) per

Benzinga Newsdesk

PRO
Protagonist Therapeutics Q1 EPS $0.05 Beats $(0.42) Estimate, Sales $56.368M Beat $16.273M Estimate

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.42) by 111.9 percent. This is a 126.32 percent increase over losses of $(0.19) per

Benzinga Newsdesk

Protagonist Therapeutics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate

Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.24) by 191.14 percent. This is a 134.85 percent decrease over earnings of $1.98 per

Benzinga Newsdesk

PRO
Protagonist Therapeutics Q3 EPS $(0.62) Beats $(0.63) Estimate, Sales $4.712M Beat $3.636M Estimate

Benzinga Newsdesk

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Vandana Singh